

STATegics Presents Positive Preclinical Results for Its Proprietary Erythropoietin Mimetic, STS-E15, at the American Academy of Neurology (AAN) 63rd Annual Meeting

Menlo Park, CA, April 12, 2011 - STATegics, Inc. today presented preclinical results for its Erythropoietin (EPO) mimetic compounds at the American Academy of Neurology (AAN) 63rd Annual Meeting being held April 9 to 16, 2011, in Honolulu, HI. The poster presentation entitled “A Non-peptidic Erythropoietin Mimetic STS-E15 Protects Primary Neurons Against 6-Hydroxydopamine or Glutamate Toxicity without Erythropoietic Activity” demonstrated beneficial neuronal effects of the company’s EPO mimetic small molecule in the absence of erythropoiesis-inducing effects of recombinant EPO. The results are also summarized in Abstract #335AAN11D1 by J. Punnonen et al. Copies of the abstract and poster presentation can be obtained by contacting the Company at information@stategics.com.